Cargando…
Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure
Infliximab is an anti-tumor necrosis factor (TNF) used for treatment of inflammatory bowel disease (IBD) as well as rheumatoid arthritis, psoriasis, and other inflammatory conditions. Antibodies to infliximab (ATI) develop in approximately 45% of infliximab-treated IBD patients and are correlated wi...
Autores principales: | Ungar, Bella, Haj-Natour, Ola, Kopylov, Uri, Yavzori, Miri, Fudim, Ella, Picard, Orit, Loebstein, Ronen, Lahat, Adi, Maor, Yaakov, Avidan, Benjamin, Lang, Alon, Weiss, Batia, Chowers, Yehuda, Eliakim, Rami, Ben-Horin, Shomron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602524/ https://www.ncbi.nlm.nih.gov/pubmed/25950682 http://dx.doi.org/10.1097/MD.0000000000000673 |
Ejemplares similares
-
Delaying an infliximab infusion by more than 3 days is associated
with a significant reduction in trough levels but not with clinical
worsening
por: Ben-Shatach, Zohar, et al.
Publicado: (2022) -
Acute Chest Pain as an Infusion Reaction to Vedolizumab
por: Levartovsky, Asaf, et al.
Publicado: (2022) -
Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
por: Levartovsky, Asaf, et al.
Publicado: (2023) -
Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study
por: Veisman, Ido, et al.
Publicado: (2021) -
Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn’s disease
por: Lahat, Adi, et al.
Publicado: (2017)